个人概况

姓  名：廖宇宁               性  别： 男

民  族：汉                 导师层次：硕/博导

技术职称：副研究员             导师类型：学术型

最后学历：研究生               最后学位：博士

工作单位：广州医科大学           邮  箱：liaoyuningm1@126.com

个人简介

廖宇宁，男，副研究员，硕/博士生导师,“南山学者”骨干人才，2019年毕业于广州医科大学，获临床病理学与病理生理学博士学位。目前依托广州医科大学广东省蛋白质修饰与疾病重点实验室开展工作，主要从事蛋白质修饰与肿瘤学领域的研究，主持国家自然科学基金、广东省教育厅、广州市科技局、广州医科大学科研能力提升——优青成长等各级项目多项。近年来围绕肿瘤关键驱动蛋白的翻译后修饰及其在肿瘤代谢、生长、转移和耐药中的作用方面发表SCI论文30余篇，其中以第一和（或）通讯作者在中科院1区期刊发表SCI论著10余篇，代表性论文发表在Advanced Science（2023）, Cell Discovery （2019）, Oncogene（2018, 2021, 2025a, 2025b）, Journal of Experimental & Clinical Cancer Research （2019, 2021）和Pharmacological Research (2024)等国际知名期刊上。

研究方向

（1）翻译后修饰；（2）肿瘤代谢重编程

主持科研项目

1.国家自然科学基金面上项目，82573632，TIMM50抑制C1QBP犹素化促进前列腺癌神经内分泌转化及机制研究，2026/01-2029/12，49万元，在研，主持；

2.国家自然科学基金青年项目, 82002481, USP1-UAF1复合体调控RPS16的泛素化降解促进肝癌恶性进展，2021/01-2023/12，24万元，结题，主持；

3.广州医科大学优青培育项目，蛋白质修饰与肿瘤，2023/01-2024/12，100 万元，结题，主持；

4.广州市科技计划基础与应用基础研究项目, 202102020931, 去泛素化酶USP1调控肝癌细胞生长和侵袭转移的分子机制研究，2021/04-2023/03，5万元，结题，主持；

5.广东省普通高校青年创新人才类项目, 2019KQNCX113, 核糖体蛋白降解调控在肝癌治疗中的作用及其分子机制研究，2020/01-2022/12，2.5万元，结题，主持。

代表性第一和通讯作者论文：

1. Huang H#*, Xiang Y#, Deng Y#, Liu Q, Cai G, Lei Q, Sun W, Yin S, Li Y, Peng E, Yao Y, Yao L, Xu D, Shao Z, Liao Y*. WBP11 inhibits UFL1-mediated UFMylation of NONO to drive hepatocellular carcinoma progression. Oncogene. 2025, 44(48):4673–4685. (IF 7.3, 中科院1区)

2. Huang H#*, Zhuang X#, Yin S#, Sun W, Cheng J, Peng EY, Xiang Y, He X, Tang M, Li Y, Yao Y, Deng Y, Liu Q, Shao Z, Xia X, Cai G*, Liao Y*. The Ku70-SIX1-GPT2 axis regulates alpha-ketoglutarate metabolism to drive progression of prostate cancer. Oncogene. 2025, 44(2):92–104. (IF 7.3, 中科院1区)

3. Zhuang X#, Yin S#, Cheng J#, Sun W, Fang Z, Xiang Y, Peng EY, Yao Y, Li Y, He X, Lu L, Deng Y, Huang H*, Cai G*, Liao Y*. METTL14-mediated m6A modification enhances USP22-ERα axis to drive breast cancer malignancy. Pharmacological Research. 2024; 210:107509. (IF 10.5, 中科院1区)

4. Shao Z#, Liu S#, Sun W#, Zhuang X, Yin S, Cheng J, Xia X, Liao Y*, Liu J*, Huang H*. SENP3 mediates deSUMOylation of SIX1 to promote prostate cancer proliferation and migration. Cellular & Molecular Biology Letters. 2024;29(1):146. (IF 10.2, 中科院1区)

5. Liao Y#*, Liu Y#, Yu C#, Lei Q, Cheng J, Kong W, Yu Y, Zhuang X, Sun W, Yin S, Cai G*, Huang H*. HSP90β Impedes STUB1-Induced Ubiquitination of YTHDF2 to Drive Sorafenib Resistance in Hepatocellular Carcinoma. Advanced Science, Sep;10(27):e2302025. (IF 14.1, 中科院1区)

6. Liu Y#, Kong W#, Yu C#, Shao Z, Lei Q, Deng Y, Cai G, Zhuang X, Sun W, Wu S, Wang R, Chen X, Chen G*, Huang H*, Liao Y*. SNS-023 sensitizes hepatocellular carcinoma to sorafenib by inducing degradation of cancer drivers SIX1 and RPS16. Acta Pharmacologica Sinica, 2023 Apr;44(4):853-864. (IF 8.4, 中科院1区)

7. Liao Y#, Sun W#, Shao Z#, Liu Y, Zhong X, Deng Y, Liu F, Huang H*, Liu J*. A SIX1 degradation inducer blocks excessive proliferation of prostate cancer. International Journal of Biological Sciences, 2022 Mar 14; 18(6): 2439-2451. (IF 10, 中科院1区)

8. Liao Y#, Shao Z#, Liu Y#, Xia X, Deng Y, Yu C, Sun W, Kong W, He X, Liu F, Guo Z, Chen G, Tang D, Gan H*, Liu J*, Huang H*. USP1-dependent RPS16 protein stability drives growth and metastasis of human hepatocellular carcinoma cells. Journal of Experimental & Clinical Cancer Research, 2021 Jun 21;40(1):201. (IF 12.8, 中科院1区)

9. Liao Y#, Liu Y#, Shao Z#, Xia X, Deng Y, Cai J, Yao L, He J, Yu C, Hu T, Sun W, Liu F, Tang D, Liu J*, Huang H*. A new role of GRP75-USP1-SIX1 protein complex in driving prostate cancer progression and castration resistance. Oncogene, 2021 Jun 2. (IF 7.3, 中科院1区)

10. Liu Y#, Yu C#, Shao Z, Xia X, Hu T, Kong W, He X, Sun W, Deng Y, Liao Y*, Huang H*. Selective degradation of AR-V7 to overcome castration resistance of prostate cancer. Cell Death & Disease. 2021;12(10):857. (IF 9.6, 中科院1区)

11. Liao Y#, Liu Y#, Xia X#, Shao Z, Huang C, He J, Jiang L, Tang D, Liu J*, Huang H*. Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy. Theranostics, 2020 Feb 10; 10(8):3366-3381. (IF 13.3, 中科院1区)

12. Liao Y#, Liu N#, Xia X, Guo Z, Li Y, Jiang L, Zhou R, Tang D, Huang H*, Liu J*. USP10 modulates the SKP2/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia. Cell Discovery, 2019 Apr 30;5:24. (IF 13, 中科院1区)

13. Liao Y#, Guo Z#, Xia X#, Liu Y, Huang C, Jiang L, Wang X, Liu J*, Huang H*. Inhibition of EGFR signaling with Spautin-1 represents a novel therapeutics for prostate cancer. Journal of Experimental & Clinical Cancer Research, 2019 Apr 11;38(1):157. (IF 12.8, 中科院1区)

14. Liao Y#, Xia X#, Liu N#, Cai J, Guo Z, Li Y, Jiang L, Dou Q, Tang D, Huang H*, Liu J*. Growth arrest and apoptosis induction in androgen receptor-positive human breast cancer cells by inhibition of USP14-mediated androgen receptor deubiquitination. Oncogene, 2018 Apr;37(14):1896-1910. (IF 7.3, 中科院1区)

15. Liao Y#, Liu N, Hua X, Cai J, Xia X, Wang X, Huang H*, Liu J*. Proteasome-associated deubiquitinase ubiquitin-specific protease 14 regulates prostate cancer proliferation by deubiquitinating and stabilizing androgen receptor. Cell Death & Disease, 2017 Feb 2;8(2):e2585. (IF 9.6, 中科院1区)

（注：#第一作者，*通讯作者）